The rising awareness about adverse effects caused by prolonged cancer treatment is expected to boost the growth of the cancer supportive care drugs market during the forecast period.

Cancer supportive care drugs offer wraparound care for cancer patients, and they also help healthcare administration navigate the illness. Cancer supportive care is a well-recognized discipline that plays around multiple aspects of medical care, including the physical, psychological, and mental issues cancer patients face. The evolution of supportive oncology has focused on the improvement of cancer-supportive care drugs that can indicate the urgency of pain.

Cancer supportive care drugs are widely used, and oncologists prefer to use them right away after a cancer diagnosis. According to the National Cancer Institute, supportive care drugs can improve both physical and mental health.

Supportive care drugs have been shown to include post-therapy care for cancer patients. Cancer supportive care drugs help cancer patients avoid treatment side effects and complications. Chemotherapy is one of the most effective cancer treatments or therapies. Prolonged chemotherapy, on the other hand, may increase toxicity and reduce quality of life; supportive cancer care drugs address these side effects of cancer treatment. Therapists, palliative care specialists, nutritionists, pain care specialists, and medical advisors participate in the supportive cancer care drugs or medicines delivery sessions. Cancer-supportive care medications have the potential to improve healthcare outcomes and quality of life.

 

Cancer Supportive Care Drugs Market REPORT SCOPE & SEGMENTATION

Report Attribute

Details

Estimated Market Value (2022)

20.96 Bn

Projected Market Value (2031)

25 Bn

Base Year

2022

Forecast Years

2023 - 2031

Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- By Therapeutic Class, By Distribution Channel, By Application & By Region

Segments Covered

By Therapeutic Class, By Distribution Channel, By Application & By Region

Forecast Units

Value (USD Billion), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2023 to 2031

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.

Delivery Format

Delivered as an attached PDF and Excel through email, according to the purchase option.

 

Growth Factors:

The global supportive care drugs market is expected to undergo a significant shift during the forecast period as the supportive oncology sector improves globally. In the last two decades, an unhealthy diet and sedentary lifestyles have increased the prevalence of cancer across the globe. According to the World Health Organization (WHO), approximately 4 lakh children develop cancer each year. Cancer patients' pain and side effects are reduced by supportive care drugs; the rising prevalence of childhood cancer is expected to increase demand for supportive care drugs in the healthcare sector.

The growing concern about cancer-related mortality has pushed the oncology sector to provide advanced and accountable treatment for cancer patients; the global focus on oncology research is fueling the growth of the cancer-supportive care drugs market. Various cancer treatments frequently have serious adverse effects on the human body, and rising awareness about the severe side effects caused by prolonged cancer treatment is driving market growth.

Cancer supportive care drug demand is expected to rise in high-income countries where comprehensive healthcare services are widely available. The rising preference for targeted molecule therapies for cancer patients, on the other hand, will stifle the growth of the cancer-supportive care drugs market.

 

Key Benefits of the Report

  • This study presents an analytical depiction of the Cancer Supportive Care Drugs industry along with current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to market key drivers, restraints, and opportunities, along with detailed analysis of the Cancer Supportive Care Drugs Market share.
  • The current market is quantitatively analyzed to highlight the Cancer Supportive Care Drugs Market's growth scenario.
  • Porter's five forces research demonstrates the market power of suppliers and buyers.
  • The report provides a detailed Cancer Supportive Care Drugs market analysis based on competitive intensity and how the competition will take shape in the coming years.

 

Regional Analysis:

North America holds the largest share of the global market for cancer supportive care drugs; Over the analyzed period, the region is expected to maintain its dominance. The rapid adoption of pharmaceutical industry advancements is seen as a significant driver of the growth of the cancer supportive care drugs market in North America. The presence of well-established vendors in the supportive care market will keep North America's dominance in the cancer supportive care drugs market throughout the forecast period. Furthermore, rising preferences for supportive care for newly diagnosed cancer patients are driving market growth in North America. However, strict restrictions on opioid prescription and sale are impeding the growth of the cancer supportive care drugs market in North America.

Because of the increasing demand for supportive care in the oncology sector, Asia Pacific is the fastest-growing region of the global cancer supportive care drugs market. Chemotherapy is widely used to treat cancer patients in the region. The rising number of chemotherapies in urban areas is expected to drive growth in the Asia Pacific cancer supportive care drugs market. Furthermore, rising vendor investments in oncology research will drive market growth in Asia Pacific.

Germany, England, and the United Kingdom are expected to contribute the most to Europe's cancer supportive care drugs market. The rapid increase in female breast cancer cases has increased demand for cancer supportive care drugs and palliative care in the region. Several private companies and governmental organizations are investing heavily in R&D activities in the oncology research sector in order to provide more advanced and dependable treatment for cancer patients; this factor is expected to fuel market growth in Europe during the forecast period. The European research community and healthcare sector are focused on implementing targeted therapies for cancer patients; this factor is likely to stymie the region's growth in the cancer supportive care drugs market.

Competitive Landscape

The report provides a competitive landscape on both the quantitative and qualitative research of the Cancer Supportive Care Drugs Market. The report also provides detailed insights on the development methods used by the key market players. The report offers deep research on the key market players and details on the competitiveness of these players. The main business strategies used by these players, such as mergers and acquisitions (M&A), collaborations, affiliations, and contracts, are also discussed and analyses in the report. For each competitor, the report studies their global presence, service offerings, competitors, and specifications. The main players covered by the study on the global electrical equipment market are:

  • Merck & Co.
  • Novartis AG
  • F. Hoffman-La Roche AG
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Helsin Healthcare SA
  • Baxter International Inc

 

Cancer Supportive Care Drugs Market Report Segmentation

ATTRIBUTE

DETAILS

By Therapeutic Class

  • ESA (Erythropoiesis Stimulating Agents)
  • G-CSFs (Granulocyte Colony Stimulating Factors)
  • Antiemetics
  • Bisphosphonates
  • Opioids
  • NSAIDs (Non-Steroidal Auto Inflammatory Drugs)

By Application

  • Breast Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Prostate Cancer

By Distribution Channel

  • Drug pharmacies/ Retail pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Customization Scope

  • Available upon request

Pricing

  • Available upon request

 

The Report Answers Questions Such As:

  • What is the potential opportunity for the Cancer Supportive Care Drugs Market.
  • What are the major drivers, restraints, and opportunities of the Cancer Supportive Care Drugs Market.
  • What is the market share of the leading segments and sub-segments of the Cancer Supportive Care Drugs Market in the forecast period (2023-2031).
  • How is each segment of the Cancer Supportive Care Drugs Market expected to grow during the forecast period.
  • What is the expected revenue to be generated by each of the segments by the end of 2031.
  • What are the key development strategies implemented by the key players to stand out in this Cancer Supportive Care Drugs Market.
  • What is the preferred business model used for building Cancer Supportive Care Drugs Market.
  • Which area of application is expected to be the highest revenue generator in the Cancer Supportive Care Drugs Market during the forecast period.
  • Which end-user segment is expected to be the highest revenue generator in this industry during the forecast period.
  • What is the potential of Cancer Supportive Care Drugs Market in the emerging countries during the forecast period.